Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACXP NASDAQ:ALLR NASDAQ:KZIA NASDAQ:VYNE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACXPAcurx Pharmaceuticals$2.06-3.0%$3.04$1.33▼$21.00$5.94M-2.092.22 million shs21,117 shsALLRAllarity Therapeutics$1.53+2.3%$1.21$0.77▼$2.35$23.65M0.38166,141 shs131,430 shsKZIANovogen$14.15+5.5%$9.24$3.19▼$17.40$23.34M2.22222,298 shs85,282 shsVYNEVYNE Therapeutics$0.66-1.6%$0.61$0.28▼$1.96$22.09M2299,874 shs9,755 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACXPAcurx Pharmaceuticals+1.44%-1.85%-30.94%-3.20%-70.10%ALLRAllarity Therapeutics+1.35%+11.11%+29.31%+80.57%+46.34%KZIANovogen-3.11%-1.69%+39.40%+131.61%+311.98%VYNEVYNE Therapeutics+0.58%+5.78%+13.58%+20.35%-50.84%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACXPAcurx Pharmaceuticals$2.06-3.0%$3.04$1.33▼$21.00$5.94M-2.092.22 million shs21,117 shsALLRAllarity Therapeutics$1.53+2.3%$1.21$0.77▼$2.35$23.65M0.38166,141 shs131,430 shsKZIANovogen$14.15+5.5%$9.24$3.19▼$17.40$23.34M2.22222,298 shs85,282 shsVYNEVYNE Therapeutics$0.66-1.6%$0.61$0.28▼$1.96$22.09M2299,874 shs9,755 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACXPAcurx Pharmaceuticals+1.44%-1.85%-30.94%-3.20%-70.10%ALLRAllarity Therapeutics+1.35%+11.11%+29.31%+80.57%+46.34%KZIANovogen-3.11%-1.69%+39.40%+131.61%+311.98%VYNEVYNE Therapeutics+0.58%+5.78%+13.58%+20.35%-50.84%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACXPAcurx Pharmaceuticals 2.00Hold$31.001,407.78% UpsideALLRAllarity Therapeutics 2.00Hold$9.75535.59% UpsideKZIANovogen 2.50Moderate Buy$21.0048.46% UpsideVYNEVYNE Therapeutics 1.75ReduceN/AN/ACurrent Analyst Ratings BreakdownLatest ACXP, KZIA, VYNE, and ALLR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026VYNEVYNE Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026KZIANovogen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026ACXPAcurx Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026ALLRAllarity Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/15/2026KZIANovogen LaidlawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$25.004/10/2026ALLRAllarity Therapeutics Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.50 ➝ $9.75(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACXPAcurx PharmaceuticalsN/AN/AN/AN/A$2.07 per shareN/AALLRAllarity Therapeutics$320K74.11N/AN/A$0.61 per share2.51KZIANovogen$30K777.98N/AN/A($5.34) per share-2.65VYNEVYNE Therapeutics$570K38.76N/AN/A$0.83 per share0.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACXPAcurx Pharmaceuticals-$7.97M-$5.63N/AN/AN/AN/A-215.54%-128.70%5/12/2026 (Estimated)ALLRAllarity Therapeutics-$11.23M-$0.80N/AN/AN/AN/A-85.29%-49.92%5/8/2026 (Estimated)KZIANovogen-$13.41MN/AN/AN/AN/AN/AN/AN/AN/AVYNEVYNE Therapeutics-$26.48M-$0.78N/AN/AN/A-4,646.14%-74.86%-63.87%N/ALatest ACXP, KZIA, VYNE, and ALLR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026ACXPAcurx Pharmaceuticals-$0.59N/AN/AN/AN/AN/A5/8/2026N/AALLRAllarity Therapeutics-$0.22N/AN/AN/A$0.32 millionN/A3/30/2026Q4 2025ALLRAllarity Therapeutics-$0.22-$0.21+$0.01-$0.21N/AN/A3/19/2026Q2 2026KZIANovogenN/A-$1.34N/A-$1.34N/AN/A3/12/2026Q4 2025ACXPAcurx Pharmaceuticals-$1.01-$0.31+$0.70-$0.31N/AN/A2/27/2026Q4 2025VYNEVYNE TherapeuticsN/A-$0.1490N/A-$0.1490N/A$0.13 million2/14/2026Q2 2026KZIANovogenN/A-$1.34N/A-$1.34N/A$4.89 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACXPAcurx PharmaceuticalsN/AN/AN/AN/AN/AALLRAllarity TherapeuticsN/AN/AN/AN/AN/AKZIANovogenN/AN/AN/AN/AN/AVYNEVYNE TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACXPAcurx PharmaceuticalsN/A3.183.18ALLRAllarity TherapeuticsN/A2.132.13KZIANovogenN/A2.87N/AVYNEVYNE TherapeuticsN/A12.5312.53Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACXPAcurx Pharmaceuticals11.53%ALLRAllarity Therapeutics11.53%KZIANovogen30.89%VYNEVYNE Therapeutics83.78%Insider OwnershipCompanyInsider OwnershipACXPAcurx Pharmaceuticals20.30%ALLRAllarity Therapeutics0.08%KZIANovogen1.00%VYNEVYNE Therapeutics3.03%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACXPAcurx Pharmaceuticals32.86 million2.28 millionNo DataALLRAllarity Therapeutics1015.46 million15.45 millionNot OptionableKZIANovogen121.65 million1.64 millionNo DataVYNEVYNE Therapeutics3033.32 million32.31 millionNot OptionableACXP, KZIA, VYNE, and ALLR HeadlinesRecent News About These CompaniesShareholder Alert: The Ademi Firm investigates whether VYNE Therapeutics Inc. is obtaining a Fair Price for its Public ShareholdersDecember 18, 2025 | prnewswire.com3 penny stocks to watch now, 12/18/25December 18, 2025 | msn.comVYNE to merge with Yarrow in $200 million dealDecember 18, 2025 | thepharmaletter.comTRoundup: Harbor BioMed Announces Collaboration and License Agreement with Bristol Myers, Squibb, VYNE Therapeutics Enters Merger Agreement with Yarrow BioscienceDecember 17, 2025 | pharmexec.comP$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of VYNE Therapeutics Inc. (NASDAQ: VYNE)December 17, 2025 | prnewswire.comVYNE Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of VYNE Therapeutics Inc. is Fair to ShareholdersDecember 17, 2025 | businesswire.comVYNE Therapeutics Inc. (VYNE) Yarrow Bioscience, Inc. - M&A Call Prepared Remarks TranscriptDecember 17, 2025 | seekingalpha.comVyne Therapeutics stock soars after merger with Yarrow BioscienceDecember 17, 2025 | za.investing.comVyne Therapeutics, Yarrow Bioscience to MergeDecember 17, 2025 | marketwatch.comVyne Therapeutics shares surge on merger deal with Yarrow BioscienceDecember 17, 2025 | msn.comVYNE Therapeutics and Yarrow Bioscience Announce Merger AgreementDecember 17, 2025 | globenewswire.comVYNE Therapeutics Approves Director Elections and ProposalsDecember 12, 2025 | tipranks.comVYNE Therapeutics reports Q3 EPS (17c) vs (29c) last yearNovember 6, 2025 | msn.comVYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue EstimatesNovember 6, 2025 | zacks.comVYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business UpdateNovember 6, 2025 | globenewswire.comIncyte scraps BET inhibitor against backdrop of safety concerns for the drug classOctober 28, 2025 | fiercebiotech.comFVYNE Therapeutics (VYNE) Price Target Decreased by 22.00% to 3.32October 1, 2025 | msn.comVYNE Therapeutics Faces Nasdaq Non-Compliance NoticeSeptember 12, 2025 | msn.comVYNE Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues LagAugust 19, 2025 | finance.yahoo.comVitiligo Clinical Trial Pipeline Accelerates as 18+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsightAugust 14, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACXP, KZIA, VYNE, and ALLR Company DescriptionsAcurx Pharmaceuticals NASDAQ:ACXP$2.06 -0.06 (-3.02%) As of 11:09 AM Eastern This is a fair market value price provided by Massive. Learn more.Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.Allarity Therapeutics NASDAQ:ALLR$1.53 +0.03 (+2.27%) As of 11:12 AM Eastern This is a fair market value price provided by Massive. Learn more.Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.Novogen NASDAQ:KZIA$14.14 +0.74 (+5.48%) As of 11:10 AM Eastern This is a fair market value price provided by Massive. Learn more.Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.VYNE Therapeutics NASDAQ:VYNE$0.66 -0.01 (-1.56%) As of 11:11 AM Eastern This is a fair market value price provided by Massive. Learn more.VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
